Clovis CMO Allen exits for biotech startup; Forum's schizophrenia drug put on FDA's fast track;

@FierceBiotech: Vical shares decimated (again) after herpes vaccine flunks a PhI/II trial. More | Follow @FierceBiotech

@JohnCFierce: Remember that #biotech #IPO pullback we thought we'd see this year? Didn't happen - yet. #blazing. Story | Follow @JohnCFierce

@DamianFierce: Reminder that Chris Viehbacher, now riding high, got ghosted out of lunch by the $SNY board. Image | Follow @DamianFierce

> Clovis Oncology ($CLVS) CMO Andrew Allen has departed the cancer drug company with plans to start his own biotech focused on immuno-oncology. Lindsey Rolfe was named to the post. "I always knew this day would come and that Andrew would eventually pursue his interest in starting and running his own company," said Clovis CEO Patrick Mahaffy. Release

> Waltham, MA-based Forum Pharmaceuticals, formerly EnVivo, has won fast-track status for encenicline, its experimental therapy for schizophrenia. Release

> China's 3SBio has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody technology. 3SBio previously acquired the China rights from Apexigen in 2006. Release

Medical Device News

@FierceMedDev: Siemens snags FDA approval for HIV combo test. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: MIT to launch nonprofit focused on empirical evaluation of digital health products. Article | Follow @VarunSaxena2

@EmilyWFierce: Bill Ackman and other philanthropists sink $20M into project @broadinstitute for drug-resistant TB. Article from FierceDiagnostics | Follow @EmilyWFierce

> Broad Institute gets $20M to target TB from Wall Street-led philanthropists. Article

> U.K. NHS spinout Touch Bionics launches smarter, faster, stronger prosthetic hand. Report

Pharma News

@FiercePharma: NICE's cost watchdogs favor biosims for RA ahead of Remicade. Story | Follow @FiercePharma

@EricPFierce: See which companies had the most Class I recalls in recent years. FiercePharmaManufacturing feature | Follow @EricPFierce

> EU slaps Chinese amoxicillin maker with import ban. Article

> Emerging markets still beat elsewhere for Big Pharma growth, with AstraZeneca in the lead. More

Pharma Manufacturing News

> China not only source for counterfeit drugs but also for meth, other synthetics. Report

> Russian company building blood products plant. Item

> Baxter recalling subpotent heparin. Story

> Akorn's Hi-Tech source of another recall. More

> Europe bans some APIs from Chinese drugmaker Zhuhai United. Article

Drug Delivery News

> Bayer studies eye drug delivery in collaboration with Johns Hopkins. Item

> IPOs: Celyad rakes in $100M, Neos shoots for $69M. More

> Harvard team makes 'sweating' vehicles for liquid drug delivery. Story

> Canadian team developing drug-delivering contact lens. Article

> Teva partners with Microchips Biotech to deliver drugs via wirelessly controlled implant. Report

Pharma Asia News

> Asia's emerging biotech scene begs for a look at Kobe, Biocom's Panetta says. More

> Foreign investors allowed up to 44% of India's Syngene IPO shares. Report

> Vietnam gets official WHO nod as global vaccine supplier. Story

> J&J, Stryker, Zimmer in line as India eyes price caps on orthopedic implants. Article

> Package inserts on endoscopes revised in Japan. Item

Suggested Articles

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.